About Newronika
Newronika is a company based in Cologno Monzese (Italy) founded in 2016 by Alberto Priori. Newronika has raised $25.24 million across 5 funding rounds from investors including Intesa Sanpaolo, European Union and ENEA Tech e Biomedical. Newronika offers products and services including AlphaDBS, FilterDBS, and WebBioBank. Newronika operates in a competitive market with competitors including NovaVision, MindAffect, EnClear Therapies, Actipulse Neuroscience and AccuMedical, among others.
- Headquarter Cologno Monzese, Italy
- Founders Alberto Priori
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Newronika S.P.A.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$25.24 M (USD)
in 5 rounds
-
Latest Funding Round
$14.11 M (USD), Series B
Feb 13, 2025
-
Investors
Intesa Sanpaolo
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Newronika
Newronika offers a comprehensive portfolio of products and services, including AlphaDBS, FilterDBS, and WebBioBank.
Adaptive implant for real-time brain stimulation adjustment.
Records noise-free brain signals during stimulation.
Cloud platform for collecting and analyzing biosignal data.
People of Newronika
Unlock access to complete
Clinical Team
1 people
Firmware Team
1 people
Software Development Team
1 people
Finance and Accounting
1 people
Unlock access to complete
Funding Insights of Newronika
Newronika has successfully raised a total of $25.24M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $14.11 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Newronika
Newronika has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Intesa Sanpaolo, European Union and ENEA Tech e Biomedical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital investments are managed by Indaco in Italy.
|
Locked | Locked | Locked | |
|
VC firm investing in seed and early stage companies in Italy
|
Locked | Locked | Locked |
Investor details for Newronika
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Newronika
Investment portfolio details for Newronika
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Newronika
Detailed financials for Newronika
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Newronika Comparisons
Peer comparison for Newronika
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Newronika
Newronika operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NovaVision, MindAffect, EnClear Therapies, Actipulse Neuroscience and AccuMedical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Non-invasive devices are developed for vision restoration in stroke survivors.
|
|
| Locked | Locked | Locked |
Brain-computer interface headsets are developed for patient communication.
|
|
| Locked | Locked | Locked |
Developer of device-based therapies to treat neurodegenerative disorders
|
|
| Locked | Locked | Locked |
Non-invasive brain stimulation technology is developed for neurodegenerative disorders.
|
|
| Locked | Locked | Locked |
Neurovascular interventional devices for neurological disorders are developed.
|
Detailed competitors of Newronika
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Newronika
Complete news archive for Newronika
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Newronika
Newronika was founded in 2016.
Newronika is headquartered in Cologno Monzese, Italy. It is registered at Cologno Monzese, Lombardy, Italy.
Lorenzo Rossi is the current CEO of Newronika.
Newronika is a funded company, having raised a total of $25.24M across 5 funding rounds to date.
Newronika was founded in 2016 in Cologno Monzese, Italy, within the medical technology sector. Devices addressing neurodegenerative diseases are created, including AlphaDBS, a closed-loop deep brain neuromodulation system designed to interpret bioelectrical neuronal activity. WebBioBank, a web-based platform, is employed by researchers for collecting, analyzing, and interpreting biosignals alongside electronic health records from patients in neuromodulation treatments. Operations center on advancing therapeutic tools for neurological conditions.
Newronika's top competitors include NovaVision, Actipulse Neuroscience and EnClear Therapies.
Newronika offers AlphaDBS, FilterDBS, and WebBioBank.
Newronika has 11 investors. Key investors include Intesa Sanpaolo, European Union, ENEA Tech e Biomedical, Indaco Venture Partners, and Innogest Capital.